NEW YORK: Abcam has entered a global distribution agreement to sell Avacta's recently developed SARS-CoV-2 research ELISA Affimer reagents, Avacta said on Tuesday.
Under the non-exclusive distribution agreement, Cambridge, UK-based Abcam will sell Avacta’s SARS-CoV-2 spike protein Affimer research reagents.